There's really no such thing as a “no brainer” stock pick. I'd say that some opportunities are more compelling than others.
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.
![]() ABBV In 3 days Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (In 1 week) Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
![]() ABBV In 3 days Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (In 1 week) Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | NYSE Exchange | 00287Y109 Cusip |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.